Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Branded drug inventory is a balancing act—until patent cliffs turn it into a gamble.
For wholesalers, the risk isn’t theoretical. It’s operational, financia…

Big Pharma doesn’t just “hire.” It signals.
And one of the most underappreciated signals is what happens around the patent cliff—when blockbuster protections expire, margins compress, and the future suddenly becomes a hiring plan, not a slide deck.
A n…

Biosimilar switching isn’t a procurement problem—it’s an IP strategy problem.
If you’re planning a biosimilar switch this year, here’s the uncomfortable truth: most teams don’t lose because the biosimilar isn’t available. They lose because the timing i…

Pharma has a familiar playbook: take an old molecule, reframe the evidence, and sell it as something new.
That’s the core tension behind “old drugs, new prices”—and it’s showing up more often as companies repurpose existing therapies for new indication…

Pharma recruiters don’t just “find talent.” They find signal.
In a market where everyone claims they’re building the next breakthrough, the real differentiator is often quieter: who has been cited—again and again—by the scientific record.
That’s the co…

Pharma has a new playbook for “old” drugs: repackage them as “new” again—and justify premium pricing with a straight face.
That’s the core tension behind the latest discussion from DrugPatentWatch: how companies can take repurposed medicines—therapies …

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in the global drug supply chain. In practice, it’s a signal flare—one that can help investors, manufacturers, and policymakers anticipate where Russia is headed next in APIs and full-cycle drug p…

Big Pharma doesn’t always “win” in court. Sometimes it just keeps the clock running.
Europe’s divisional patent strategy—where companies split one patent application into multiple “divisional” filings—has become a powerful tool to delay final decisions…

Pharma patent litigation used to be a rite of passage—an expensive one.
For years, the industry treated legal spend as an unavoidable cost of doing business: file, fight, appeal, repeat. But the economics are changing fast. According to recent analysis…